Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Steps Up Try To Regain Leading Role In iPS Research

This article was originally published in PharmAsia News

Executive Summary

Japan is making an additional effort to regain its standing as a leader in the study of induced pluripotent stem cells by tying in with foreign institutions. Kyoto University is discussing a possible alliance with Harvard University of the United States for joint iPS study. The school also expects to begin a joint study of diabetic treatment soon with Novocell, a U.S. biotech. The new alliances come on top of a Kyoto U. link with the University of Toronto in Canada last year. Japan has felt a sense of urgency to step up its iPS research after losing the lead in the field to other countries where laboratories reported great strides last year. (Click here for more - a subscription may be required)

You may also be interested in...

Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts